- Tetra Bio-Pharma (TBP) will receive up to C$150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
- The award follows $4.5 million from the Government of Quebec
- The funds will support development programs for Tetra’s ARDS-003 formulation
- ARDS-003 is intended to modulate acute systemic inflammation and prevent sepsis, organ damage, and acute respiratory distress syndrome
- Tetra Bio-Pharma specializes in cannabinoid-derived drug discovery and development
- Tetra Bio-Pharma (TBP) opened with a gain of 25 per cent, trading at $0.025 per share
Tetra Bio-Pharma (TBP) will receive up to C$150,000 in funding from the NRC IRAP.
The funds will support a research and development project for its ARDS-003 oral formulation, including formulation optimization and animal non-GLP pharmacokinetic studies.
The award follows $4.5 million from the Government of Quebec for the clinical development of ARDS-003 to treat acute respiratory distress syndrome (ARDS).
ARDS-003 is the First in-Human drug product containing Onternabez, a full agonist of the type 2 cannabinoid receptor. ARDS-003 is intended to modulate acute systemic inflammation and prevent sepsis, ARDS, and organ damage. Tetra’s ARDS-based pre-clinical studies demonstrated that its formulation slows disease progression.
“We are grateful to receive this funding, which will support the development of the ARDS-003 oral program by investigating safety, pharmacokinetics, and pharmacodynamics,” stated Dr. Guy Chamberland, Tetra’s CEO and Chief Regulatory Officer.
Tetra Bio-Pharma specializes in cannabinoid-derived drug discovery and development. Its product pipeline currently seeks to address pain, inflammation and oncology.
Tetra Bio-Pharma (TBP) opened with a gain of 25 per cent, trading at $0.025 per share.